Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis

Table 1 The prevalence of Hepatitis C infection in Middle-East countries. Summary of studies by countries¹, age and hemodialysis duration are presented

Subgroup	Number of studies	Prevalence (95%CI)	Between studies		Between subgroups
			I2	PHeterogeneity	Q	PHeterogeneity
Country
Iran	21	12% (10%-15%)	90.0%	0.001	30052.52	0.001
Iraq	9	20% (12%-28%)	97.3%	0.001
Egypt	7	50% (46%-55%)	94.7%	0.001
Jordan	4	35% (17%-54%)	97.4%	0.001
Yemen	4	42% (28%-56%)	93.4%	0.001
Turkey	4	23% (18%-28%)	66.3%	0.031
Palestine	3	18% (5%-30%)	94.8%	0.001
Lebanon	2	9% (1%-17%)	98.4%	0.001
Syria	1	54% (50%-59%)	-	-
Saudi	1	19% (13%-25%)	-	-
Age(yr)
< 40	4	24% (11%-38%)	95.4%	0.001	334.82	0.001
40-50	16	35% (26%-45%)	97.8%	0.001
≥ 50	26	20% (10%-29%)	99.7%	0.001
Hemodialysis duration (yr)
< 3	13	22% (15%-29%)	96.4%	0.001	3085.57	0.001
3-5	8	22% (4%-40%)	99.7%	0.001
≥ 5	9	30% (16%-45%)	99.0%	0.001

¹United Arab Emirates, Afghanistan, Qatar, Bahrain, Kuwait, Oman, Israel, and Cyprus, were not added due to insufficient data. The prevalences are reported as ratio (95%CI).